SavedAdd your journal

Journals / Türk Patoloji Dergisi / 2022 / Cilt: 38 - Sayı: 2

GLUT-1 Expression in Breast Cancer

Bayram ŞEN
Recep BEDİR
Gülname FINDIK GÜVENDİ
Oğuzhan OKÇU
Çiğdem ÖZTÜRK
Pages
114–121
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: GLUT-1 expression was correlated with poor prognostic factors such as estrogen receptor and progesterone receptor negativity, high Ki-67 proliferation index, and high histological and nuclear grade (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Numerous studies have been conducted to predict the prognosis of breast cancers.
📊
Key Findings & Data:The effect of glucose transporter protein 1 (GLUT-1), the main carrier protein responsible for glucose transport, was investigated in breast cancer patients.
💡
Conclusion & Impact:Results: GLUT-1 expression was correlated with poor prognostic factors such as estrogen receptor and progesterone receptor negativity, high Ki-67 proliferation index, and high histological and nuclear grade (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Numerous studies have been conducted to predict the prognosis of breast cancers. The effect of glucose transporter protein 1 (GLUT-1), the main carrier protein responsible for glucose transport, was investigated in breast cancer patients. Material and Method: 170 patients operated for breast carcinoma were included in this study. We analysed the prognostic significance of GLUT-1 immune-expression in 149 patients without neoadjuvant therapy, and in 21 patients with neoadjuvant therapy. Results: GLUT-1 expression was correlated with poor prognostic factors such as estrogen receptor and progesterone receptor negativity, high Ki-67 proliferation index, and high histological and nuclear grade (p

🔖

Cite This Article

ŞEN, B., BEDİR, R., GÜVENDİ, G. F., OKÇU, O., ÖZTÜRK, Ç. (2022). GLUT-1 Expression in Breast Cancer. Türk Patoloji Dergisi, Cilt: 38 - Sayı: 2, 114–121. https://ajindex.com/articles/640341

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941-53
  2. Li J, Chen Z, Su K, Zeng J. Clinicopathological classification and traditional prognostic indicators of breast cancer. Int J Clin Exp Pathol. 2015;8:8500-5
  3. Chiche J, Brahimi-Horn MC, Pouysségur J. Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer. J Cell Mol Med. 2010;14:771-94
  4. Ancey PB, Contat C, Meylan E. Glucose transporters in cancerfrom tumor cells to the tumor microenvironment. FEBS J. 2018;285:2926-43
  5. Pragallapati S, Manyam R. Glucose transporter 1 in health and disease. J Oral Maxillofac Pathol. 2019;23:443-9
  6. Zhou JC, Zhang JJ, Zhang W, Ke ZY, Ma LG, Liu M. Expression of GLUT-1 in nasopharyngeal carcinoma and its clinical significance. Eur Rev Med Pharmacol Sci. 2017;21:4891-5
  7. Fitzgibbons PL, Dillon DA, Alsabeh R, Berman MA, Hayes DF, Hicks DG. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Arch Pathol Lab Med. 2014;138:595-601
  8. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020;38:1346-66
  9. Cirqueira MB, Moreira MA, Soares LR, Cysneiros MA, Vilela MH, Freitas-Junior R. Effect of Ki-67 on immunohistochemical classification of luminal a to luminal B subtypes of breast carcinoma. Breast J. 2015;21:465-72
  10. Bandyopadhyay S, Bluth MH, Ali-Fehmi R. Breast carcinoma: Updates in molecular profiling 2018. Clin Lab Med. 2018;38:401- 20
  11. Rakha EA, Allison KH, Ellis IO, Horii R, Masuda S, Penault- Llorca F, et al. Invasive breast carcinoma: General overview. In: Lokuhetty D, White VA, Watanabe R, Cree IA, editors. Breast Tumours, WHO Classification of Tumours. 5 ed. Lyon: IARC; 2019.82-101 12. Elston CW, Ellis IO. Patholo gical prognostic factors in breast cancer. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 1991;19:403-10
  12. Rastogi K, Singh L, Khan NA, Goyal S, Khatri A, Gupta N. Benign vascular anomalies: A transition from morphological to etiological classification. Ann Diagn Pathol. 2020;46:151506
  13. Thorens B, Mueckler M. Glucose transporters in the 21st Century. Am J Physiol Endocrinol Metab. 2010;298: E141-5